Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy
- Interventions
- Drug: Placebo Control
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT00876538
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷C.R.L.C Val d'Aurelle Service d'Oncologie Médicale, Montpellier, France
🇫🇷Centre Hospitalier de Versailles Hôpital André Mignot Service d'Hématologie-Oncologie, Le Chesnay, France
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 413
- Registration Number
- NCT00869661
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 512
- Registration Number
- NCT00868166
- Locations
- 🇧🇪
University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium
🇫🇷Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France
🇫🇷Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier, France
A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- Radiation: Preoperative RadiotherapyProcedure: Surgery
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT00865189
- Locations
- 🇫🇷
ICO Paul Papin; Oncologie Medicale., Angers, France
🇫🇷HOPITAL JEAN MINJOZ; Oncologie, Besancon, France
🇫🇷Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux, France
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00848120
- Locations
- 🇵🇭
Manila Doctors Hospital; Rheumatology Section, Manila, Philippines
🇵🇭Jose Reyes Memorial Medical Center, Manila, Philippines
🇵🇭Our Lady of Mount Carmel Medical Center, San Fernando, Philippines
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT00845832
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT00845910
A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT00846027
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 991
- Registration Number
- NCT00829166
A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT00825149